Zuellig Pharma China
2
7M
2
0.02
1
- Areas of investment
Summary
Zuellig Pharma China appeared to be the Corporate Investor, which was created in 1922. The main department of described Corporate Investor is located in the Wanchai. The company was established in Asia in China.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Zuellig Pharma China, startups are often financed by Pegasus Tech Ventures, TA Ventures, StartX (Stanford-StartX Fund). The meaningful sponsors for the fund in investment in the same round are Susquehanna International Group (SIG), Sojitz, Silicon Valley Bank.
Among the most popular portfolio startups of the fund, we may highlight Sensely. We can highlight the next thriving fund investment areas, such as InsurTech, Mobile. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The high activity for fund was in 2019. The fund is constantly included in less than 2 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 1
- Rounds per year
- 0.02
- Investments by industry
- Health Care (2)
- Information Services (1)
- Enterprise Software (1)
- Internet (1)
- Document Management (1) Show 3 more
- Investments by region
-
- United States (1)
- Singapore (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 110K
- Group Appearance index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.